Best Immuno-Oncology Conferences to Attend in 2026

Top 10 Immuno-Oncology Conferences to Attend in 2026.

Picking an immuno-oncology conference used to be simple when there were only a handful each year. Now, IO meetings pop up every month, all promising cutting-edge data and game-changing connections. The real question is not whether to attend but which ones will actually help your work move forward.

We’ve built this list to cut through the noise. Whether you’re validating biomarkers, running clinical trials, developing new therapies, or figuring out how to get IO innovations into practice, each conference below has a clear focus.

Some dig deep into science, others tackle regulatory hurdles, and a few concentrate on the commercial realities of bringing IO to patients.

Key Takeaways

• IO conferences in 2026 range from specialized biomarker summits to broad clinical meetings, each serving different professional needs across the IO ecosystem.
• Match conference choice to your role: biomarker developers should attend ImmunoMark Summit, clinical investigators benefit from ESMO IO Congress, and drug developers gain regulatory insights at SITC EU.
• Early-year conferences set emerging trends while year-end meetings synthesize progress and provide updated practice guidelines.
• Conference location affects network access: APAC venues connect you with Asian trial infrastructure, European meetings provide EU regulatory contacts, and innovation hub summits concentrate partnership opportunities.

10 Immuno-Oncology Conferences Worth Attending

To get the most out of this list, you must understand how it was prepared.

We evaluated conferences based on several factors:

• Scientific rigor and peer review standards
• Relevance to current IO challenges (biomarkers, combination therapies, novel modalities)
• Representation across the IO ecosystem (academic, industry, regulatory, clinical)
• Geographic diversity and accessibility
• Track record of featuring actionable data rather than promotional content

We prioritized meetings that deliver value across different career stages and functional roles, from bench scientists to clinical investigators to business development professionals. The conferences below span early-year kickoffs to year-end clinical summits, giving you options throughout the year.

Here’s an overview of the top immuno-oncology biomarker conferences:

The 10 Best Immuno-Oncology Conferences To Attend in 2026

Let’s kick off the detailed review, including what our own conference, Immunomark Summit.

1. ImmunoMark Summit 2026

Disclosure: ImmunoMark Summit is organized by us (Convoalign), and we’ve designed it to address the specific gap in IO meetings that focus on biomarker development and validation rather than treatment modalities alone.

When: March 5-6, 2026, UK Edition.

When’s happening next: 3-4 March 2027. Don’t miss; register now!

Where: London, UK

What makes it essential: ImmunoMark runs dual tracks on Next-Gen IO and Biomarker & Companion Diagnostics. If your work involves liquid biopsy, multi-omics, or regulatory reimbursement strategies for diagnostics, this oncology biomarker conference delivers focused content you won’t find at broader IO meetings.

The IO Biomarker Summit brings together biotech, pharma, and companion diagnostics teams, as well as diagnostics companies. Programming includes scientific talks, case studies, and commercial strategy panels designed specifically to align biomarkers with clinical development.

Best for: Biomarker scientists, companion diagnostics developers, translational researchers working at the intersection of IO and precision medicine

• Two parallel streams covered Next-Gen IO and Biomarkers & Companion Diagnostics simultaneously across both conference days.
• Sessions focused specifically on liquid biopsy, extracellular vesicle profiling, AI-driven PD-L1 standardization, and multi-omics integration approaches.
• Attracted predominantly senior professionals with 50% VP+ leadership and 60% pharma and biotech representation.
• Programming integrated scientific talks with commercial strategy panels addressing regulatory pathways, reimbursement trends, and market access.
• Convened scientists, clinical researchers, diagnostics developers, and regulatory stakeholders working on biomarker-driven clinical development.

For more details, check here.

2. AACR Immuno-Oncology Conference (AACR IO)

When: February 18–21, 2026

Where: JW Marriott Los Angeles

What makes it essential: AACR IO sits at the intersection of basic, translational, and clinical IO research. You’ll find peer-reviewed data on immunotherapy mechanisms, vaccines, cellular therapies, and inflammatory modulators, presented by top academic and industry labs.

The conference emphasizes novel targets, biomarkers, and early-phase clinical trials. If you’re designing studies or evaluating new therapeutic approaches, AACR IO gives you access to rigorous science in a format small enough to enable direct interaction with principal investigators.

Best for: IO scientists, translational researchers, and clinical trial designers looking for cutting-edge mechanistic insights

3. ESMO Immuno-Oncology Congress 2026

When: December 14–16, 2026

Where: London, UK (hybrid format available)

What makes it essential: ESMO IO Congress focuses on integrating immunotherapy into routine oncology care across solid and hematologic tumors. The programming centers on real-world IO use, combination strategies, and patient-outcome data.

You’ll find strong tracks on biomarkers, adverse-event management, and digital health tools in IO. The European Society for Medical Oncology curates content with clear pathways for translating advances into clinical practice.

Best for: Medical oncologists, clinical researchers, and regulatory professionals focused on implementation and practice guidelines

4. SITC EU Immuno-Oncology Drug Development Summit 2026

When: September 3–4, 2026

Where: Agora Cancer Research Center, Lausanne, Switzerland

What makes it essential: SITC EU focuses intensively on IO drug development, clinical trial design, and regulatory strategy. The summit features dedicated tracks on next-wave modalities, including bispecifics, antibody-drug conjugate-IO combinations, CAR-T, T-cell engagers, radioimmunotherapy, and oncolytic viruses.

Co-organized by the Society for Immunotherapy of Cancer, the meeting brings together investors, regulators, and R&D teams. You’ll get direct insight into regulatory pathways, preclinical model validation, and investor perspectives on IO development.

Best for: Biotech and pharma R&D teams, regulatory strategists, investors evaluating IO pipelines

5. IO360° Summit (Immuno-Oncology & Cell Therapy)

When: Mid-2026 (dates vary annually)

Where: Typically Europe or US

What makes it essential: IO360° covers the end-to-end IO and cell therapy ecosystem, from discovery through commercialization. The summit convenes science and business stakeholders with deep tracks in CAR-T, TCR-T, NK cells, and automated cell manufacturing.

Programming emphasizes data-driven decision-making, trial design, and market access rather than pure bench science. If you’re involved in business development, licensing, or portfolio strategy, IO360° provides the commercial context often missing from academically focused meetings.

Best for: Business development professionals, licensing teams, investors, and R&D leaders evaluating commercialization pathways

6. Summit for Cancer Immunotherapy (Summit4CI) 2026

When: March 29–31, 2026

Where: Vancouver, Canada

What makes it essential: Summit4CI limits attendance to around 350 people, creating space for deeper dialogue among scientists, clinicians, industry representatives, health economists, and patient advocates. The meeting gives equal weight to discovery science, industry development, and policy implications.

You’ll find strong programming on cost-effectiveness, access, and ethical dimensions of IO that go beyond mechanism talks. Summit4CI operates as a “society of societies” model, integrating clinical, economic, and patient-centric perspectives.

Best for: Researchers and clinicians interested in the broader context of IO implementation, health policy professionals, patient advocacy groups

7. International Cancer & Immuno-Oncology Conference (CIOC 2026)

When: March 19–21, 2026

Where: Singapore (hybrid format)

What makes it essential: CIOC brings together oncology and IO research with tracks on novel therapies, imaging, and policy, positioned at the intersection of basic research and patient care. The conference attracts Asian clinical and academic networks, making it valuable for regional trial planning and APAC-focused IO rollouts.

The hybrid format increases accessibility for early-career researchers and those building cross-regional collaborations.

Best for: Researchers planning trials in Asia-Pacific markets, early-career scientists, clinical investigators building international networks

8. World Cancer & Immuno-Oncology Conferences (Multiple Editions)

When: Various dates across mid to late year

Where: Multiple locations (Europe, MENA, Asia)

What makes it essential: These conferences provide broad oncology programming with dedicated IO tracks. You won’t get the depth of a pure-IO meeting, but you will get breadth across treatment modalities and disease types, which helps if you need context on how IO fits into the larger oncology landscape.

Locations in emerging-market hubs can provide insight into regional IO implementation challenges and opportunities.

Best for: General oncologists, multidisciplinary teams wanting IO updates alongside broader oncology content, researchers interested in emerging-market perspectives

9. Immuno-Oncology Regional Summits (Boston, Basel, and Other Innovation Hubs)

When: Throughout the year (typically 1-2 day formats)

Where: Major biotech and pharma hubs

What makes it essential: These city-anchored summits concentrate on regional innovation ecosystems. Expect strong representation from local biotech companies, venture capital firms, and pharmaceutical companies headquartered in the area.

Programming tends toward executive-level content, business development, and funding discussions rather than academic presentations. These meetings excel at partnership scouting and deal-making opportunities.

Best for: Business development professionals, venture capitalists, executives seeking partnership opportunities within specific innovation clusters

10. Magnus-Style Cancer & Immuno-Oncology Conference Series

When: Multiple dates and editions across the year

Where: APAC, Europe, Americas (various cities)

What makes it essential: This multi-venue series provides entry points for early-career researchers, students, and emerging biotech companies to present data and build professional networks. The poster-heavy programming format gives you opportunities to showcase work that might not yet be ready for larger, more competitive venues.

Multiple geographic editions let you choose based on travel logistics and regional networking priorities.

Best for: Early-career researchers, graduate students, emerging biotech companies seeking presentation opportunities and network building

How Can You Make The Most Out Of The Best Immuno-Oncology Events

Conferences represent significant investments of time and budget. Getting the most from these events requires intentional preparation and strategic follow-through. Here’s a practical checklist to help you extract maximum value:

Before the Conference

• Review the full program and agenda at least two weeks in advance
• Identify 5-10 must-attend sessions aligned with your current projects or challenges
• Research speakers presenting on topics relevant to your work
• Prepare a list of specific questions or challenges you want to address
• Set clear networking goals (e.g., “connect with three biomarker researchers” or “meet two potential collaborators”)
• Schedule meetings in advance with colleagues, vendors, or potential partners attending
• Download the conference app and review attendee lists if available
• Prepare a concise introduction explaining your work and what you’re looking for

During the Conference

• Attend the opening keynote to understand conference themes and priorities
• Allocate dedicated time for poster sessions, not just plenary talks
• Take targeted notes on actionable insights rather than transcribing entire presentations
• Ask questions during Q&A sessions to increase visibility and clarify complex points
• Visit exhibition halls and sponsor booths for technology demos and product updates
• Attend at least one satellite symposium or workshop for skill-building
• Participate in networking receptions, coffee breaks, and social events
• Exchange contact information with people you meet and note conversation context
• Photograph interesting posters or slides (when permitted) for later reference
• Block 30 minutes each evening to review notes and plan the next day

After the Conference

• Follow up with new contacts within one week while conversations are fresh
• Access recorded sessions or presentation slides made available to attendees
• Review and organize notes, highlighting actionable items for your team
• Share key learnings with colleagues who didn’t attend
• Implement at least one new technique, approach, or contact within 30 days
• Track relevant publications or follow-up studies mentioned during sessions
• Connect with speakers and attendees on LinkedIn or professional networks
• Evaluate whether the conference met your goals to inform future selections
• Submit abstracts or proposals for next year’s edition if relevant
• Budget and plan for follow-up conferences based on what you learned

Maximizing Specific Session Types

• Plenary sessions: Focus on big-picture trends and emerging directions rather than detailed methodology
• Poster sessions: Budget 2-3 hours minimum; these often contain cutting-edge data not yet published
• Workshops: Bring laptops or materials needed for hands-on participation
• Panel discussions: Prepare questions in advance that address implementation challenges
• Networking events: Set a goal to have substantive conversations with 3-5 new contacts
• Exhibition floor: Identify 3-5 vendors whose technologies could solve current challenges

For Virtual or Hybrid Attendance

• Test technology and login credentials before sessions begin
• Treat virtual attendance like in-person: block calendar and minimize distractions
• Participate actively in chat functions and virtual Q&A
• Join virtual networking rooms or breakout sessions when offered
• Download materials immediately as access may expire after the conference
• Follow conference hashtags on social media for real-time insights and discussions

What to Expect from IO Conferences in 2026

Several themes will shape programming across these meetings as the field matures and addresses next-generation challenges. Understanding these trends helps you identify which sessions and discussions will be most valuable for your work:

Combination therapy strategies and sequencing

Expect sessions on IO-IO combinations and IO paired with targeted therapies, focusing on sequencing strategies, patient selection, and biomarkers predicting combination efficacy. Safety profiles and the management of overlapping toxicities will feature prominently.

Biomarker development and validation approaches

Liquid biopsy, circulating tumor DNA, tumor microenvironment profiling, and multi-omic integration will dominate meetings like ImmunoMark Summit and AACR IO. Programming will emphasize predictive versus prognostic biomarkers and regulatory frameworks for biomarker-driven trial designs.

Next-generation modalities and platforms

Bispecific antibodies, T-cell engagers, antibody-drug conjugates, and next-generation cell therapies (TCR-T, NK cells, TIL therapy) will appear across agendas. Sessions will address manufacturing scalability, patient selection, and real-world performance data.

Patient selection and adverse event management

Sessions will focus on identifying patients most likely to benefit and managing immune-related adverse events more effectively. Quality-of-life, long-term survivorship, and cost-effectiveness analyses will receive increased attention.

Regulatory pathways and commercialization realities

Programming will cover adaptive trial designs, accelerated approval pathways, real-world evidence requirements, and reimbursement strategies. Expect discussions on what works in regulatory interactions and what delays approvals.

Where Do You Go from Here?

If you’re working on biomarkers or companion diagnostics in IO, ImmunoMark Summit is built for you. We focus on what broader conferences miss: liquid biopsy, multi-omics, regulatory pathways, and commercial strategies that turn science into clinical tools.

Biomarkers determine which patients respond, which combinations work, and when to adjust treatment. ImmunoMark Summit brings together the scientists, diagnostics developers, regulators, and strategists advancing this work. Two days, two focused streams, real progress.

Click to visit the ImmunoMark Summit event page.

FAQs

Which conference offers the most comprehensive biomarker content in 2026?

ImmunoMark Summit provides dedicated dual tracks on Next-Gen IO and Biomarker & Companion Diagnostics, covering liquid biopsy, multi-omics, regulatory pathways, and commercial strategy specifically for diagnostics developers and translational researchers.

How do academic and industry-focused IO conferences differ in programming?

Academic conferences like AACR IO emphasize peer-reviewed mechanistic science and basic research, while industry meetings like SITC EU and IO360° focus on drug development, regulatory strategy, commercialization pathways, and investor perspectives alongside scientific content.

Are hybrid formats available for international attendees who cannot travel?

ESMO IO Congress and CIOC both offer hybrid formats that combine on-site and online participation. Check individual conference websites for virtual access options, as availability varies and some meetings remain fully in-person to optimize networking.

What distinguishes regional IO summits from larger international conferences?

Regional summits in cities like Boston or Basel focus on local innovation ecosystems and take a smaller format (1-2 days), emphasizing business development, partnership scouting, and executive networking rather than comprehensive scientific programming.